Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Low-power AMI (active medical implants) firms fight to retain waveband

This article was originally published in Clinica

Executive Summary

Manufacturers of ultra-low power active medical implants (ULP-AMIs) are having to fight to keep the frequency band at which their instruments have traditionally worked. National frequency regulators in Europe are challenging implant manufacturers' rights to use 9-315 kHz, arguing that this waveband could be subject to interference that could harm patients and others users of the frequency.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT070563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel